Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3059643 | 0.83 | KCNA5 (0.49) | SLC22A12CLK4KCNA5KCNH2NEK1 | |
| SCHEMBL3070252 | 0.83 | SLC22A12 (0.47) | SLC22A12CLK4KCNA5KCNH2NEK1 | |
| SCHEMBL3070246 | 0.83 | SLC22A12 (0.45) | SLC22A12CLK4KCNA5KCNH2NEK1 | |
| SCHEMBL3069611 | 0.83 | SLC22A12 (0.45) | SLC22A12CLK4KCNA5KCNH2NEK1 | |
| SCHEMBL3068139 | 0.82 | CYP11B1 (0.44) | SLC22A12CLK4KCNA5KCNH2NEK1 | |
| SCHEMBL13138810 | 0.81 | CYP1A2 (0.45) | SLC22A12CLK4KCNA5KCNH2NEK1 | |
| SCHEMBL3059630 | 0.81 | CYP1A2 (0.47) | SLC22A12CLK4KCNA5KCNH2CYP1A2 | |
| SCHEMBL3054492 | 0.80 | KCNA5 (0.47) | SLC22A12CLK4KCNA5KCNH2NEK1 | |
| SCHEMBL3070210 | 0.80 | KCNA5 (0.47) | SLC22A12CLK4KCNA5KCNH2NEK1 | |
| SCHEMBL3059650 | 0.80 | KCNA5 (0.51) | SLC22A12CLK4KCNA5KCNH2NEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101128431-B | Novel quinoline derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA NV | 2011-05-25 | — | — | CN | disclosed |
| US-7790895-B2 | Quinoline derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-07 | — | — | US | disclosed |
| US-7790895-B2 | Quinoline derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-07 | — | — | US | disclosed |
| US-7790895-B2 | Quinoline derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-07 | — | — | US | disclosed |
| US-7671065-B2 | Pyridine derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-03-02 | — | — | US | disclosed |
| US-7671065-B2 | Pyridine derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-03-02 | — | — | US | disclosed |
| US-7671065-B2 | Pyridine derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-03-02 | — | — | US | disclosed |
| CN-101128431-A | Novel quinoline derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-20 | — | — | CN | disclosed |
| CN-101128428-A | Pyridine derivatives as potassium channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-20 | — | — | CN | disclosed |
| EP-1858853-A2 | NOVEL PYRIDINE DERIVATIVES AS POTASSIUM ION CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-28 | — | — | EP | disclosed |
| EP-1853564-A1 | NOVEL QUINOLINE DERIVATIVES AS POTASSIUM ION CHANNEL OPENERS | Janssen Pharmaceutica N.V. (BE) | 2007-11-14 | — | — | EP | disclosed |
| US-20070054936-A1 | Novel quinoline derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-08 | — | — | US | disclosed |
| US-20070054936-A1 | Novel quinoline derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-08 | — | — | US | disclosed |
| US-20070054936-A1 | Novel quinoline derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-08 | — | — | US | disclosed |
| US-20070054935-A1 | Novel pyridine derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-08 | — | — | US | disclosed |
| US-20070054935-A1 | Novel pyridine derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-08 | — | — | US | disclosed |
| US-20070054935-A1 | Novel pyridine derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-08 | — | — | US | disclosed |
| WO-2006091769-A1 | NOVEL QUINOLINE DERIVATIVES AS POTASSIUM ION CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006091800-A2 | NOVEL PYRIDINE DERIVATIVES AS POTASSIUM ION CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054936-A1 | Novel quinoline derivatives as potassium ion channel openers | KCNQ1, KCNQ2, KCNJ2 | SLC22A12 1157/4885CLK4 1522/4885KCNA5 25/4885 |
| US-20070054935-A1 | Novel pyridine derivatives as potassium ion channel openers | KCNJ2, KCNQ2, KCNQ1 | SLC22A12 1756/4885CLK4 2065/4885KCNA5 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.